1. Home
  2. CAC vs HUMA Comparison

CAC vs HUMA Comparison

Compare CAC & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$40.44

Market Cap

680.5M

Sector

Finance

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$1.36

Market Cap

324.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
HUMA
Founded
1875
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
680.5M
324.0M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
CAC
HUMA
Price
$40.44
$1.36
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$47.33
$10.13
AVG Volume (30 Days)
66.1K
5.0M
Earning Date
10-28-2025
11-12-2025
Dividend Yield
4.14%
N/A
EPS Growth
9.13
N/A
EPS
3.49
N/A
Revenue
$215,172,000.00
$1,571,000.00
Revenue This Year
$44.50
N/A
Revenue Next Year
$7.03
$1,468.13
P/E Ratio
$11.61
N/A
Revenue Growth
27.50
N/A
52 Week Low
$34.53
$1.09
52 Week High
$48.82
$6.77

Technical Indicators

Market Signals
Indicator
CAC
HUMA
Relative Strength Index (RSI) 58.84 47.79
Support Level $37.87 $1.09
Resistance Level $41.60 $1.26
Average True Range (ATR) 1.08 0.11
MACD 0.21 0.03
Stochastic Oscillator 67.92 76.50

Price Performance

Historical Comparison
CAC
HUMA

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About HUMA Humacyte Inc.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: